Stock screener

FDMT

Conviction 69HealthcareScan · Mon, Aug 10, 2026
FDMT$11.18+4.00%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 570.57K
May 11May 28Jun 16Jul 6Jul 23Aug 10
4D Molecular Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.4dmoleculartherapeutics.com ↗
Price11.18
Change+4.00%
Gap-1.44%
Rel volume1.35×
Avg volume619.97K
Avg $ vol6.61M
SMA 2010.61
SMA 5010.69
SMA 2009.77
Price vs 50+4.63%
Price vs 200+14.41%
MA stackbullish
50/200 cross—
Supertrenddown · 12.00
RSI (14)56
MACD hist0.05
MACD crossbull · 0d
Stoch %K / %D88 / 62
ADX (14)14
+DI / −DI25 / 19
RSI divergence—
MACD divergence—
ATR %+6.12%
ADR %5.98%
52w high13.30
52w low5.53
From 52w high-15.94%
Above 52w low+102.17%
New 52w highNo
SqueezeOff
Bollinger width21.92%
%B0.74
Donchian pos69.65%
Donchian high11.96
Donchian low9.39
AVWAP (52w high)11.62
vs AVWAP high-3.82%
AVWAP (52w low)9.53
vs AVWAP low+17.33%
OBV trendUp
Chaikin MF (20)-0.09
Today vs 20d1.35×
Avg vol (14d)570.57K
Avg vol (20d)619.97K
Avg $ vol (20d)6.61M
Market cap556.52M
RS 3m (vs SPY)+2.56%
RS 6m (vs SPY)+14.01%
RS line new highNo
Trend template6/8
Technical rank71.7
1 week+10.80%
1 month-9.18%
3 months+10.26%
6 months+24.36%
1 year+93.43%
YTD+52.73%
P/E-3.97
P/B1.23
P/S6.53
P/FCF-5.08
EPS-2.42
Div yield—
ROE-31.01%
ROA-27.32%
Debt/Eq—
Current9.34
EV/EBITDA-3.13
Gross margin—
Net margin-164.43%
Rev growth—
EPS growth12.90%
Price target31.60
Target upside182.65%
Analyst ratingBuy
Institutional105.04%
Ent. value484.03M
Revenue3.05M
Net income-68.76M
Gross profit—
Free cash flow-109.62M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out52.28M
Employees196
ListedFri, Dec 11, 2020
Free float50.43M
Float %88.3%
Short interest11.36M
Days to cover15.5d
Short volume80.3%
Squeeze score90 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$1.01 vs −$0.97
Last surprise-4.1% miss
Setup gradeB
Conviction69 / 100
Pattern quality—
Tech rank71.7 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance13.70
Support8.97
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in FDMT

All disclosures →
No recent disclosed trades by Congress in FDMT. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in FDMT · 7 buys · 3 sells

InsiderSideShares
Kirn David
See Remarks · Common Stock · 2026-08-04
Sell26.84K
Bizily Scott
Chief Legal Officer · Stock Option (Right to Buy) · 2026-06-23
Exercise9.81K
Bizily Scott
Chief Legal Officer · Common Stock · 2026-06-23
Exercise9.81K
Bizily Scott
Chief Legal Officer · Common Stock · 2026-06-23
Sell9.81K
Chacko Jacob
Director · Stock Option (Right to Buy) · 2026-06-17
Grant50K
SBLENDORIO GLENN
Director · Stock Option (Right to Buy) · 2026-06-17
Grant50K
MILLIGAN JOHN F
Director · Stock Option (Right to Buy) · 2026-06-17
Grant75K
GRAY SUSANNAH
Director · Stock Option (Right to Buy) · 2026-06-17
Grant50K
Miller-Rich Nancy
Director · Stock Option (Right to Buy) · 2026-06-17
Grant50K
THEUER CHARLES
Director · Stock Option (Right to Buy) · 2026-06-17
Grant50K

SEC filings

EDGAR filings in FDMT · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.